Andrew Ehle is a registered patent attorney with a PhD in organic chemistry. He focuses his practice on patent law in the pharmaceutical and chemical arts. In his practice, he has experience preparing and prosecuting patents, both domestically and internationally, global patent portfolio management, freedom-to-operate analyses, and due diligence work. His work focuses on the entire timeline of pharmaceutical development, from composition of matter to second-generation filings, such as salt forms, prodrugs, polymorph crystal forms, formulation, metabolites, antibody-drug conjugates, administration routes, combination therapies, syntheses, and the like.
Drew’s knowledge covers a wide range of subject matters, including small molecules, antisense oligomers, RNA and DNA analogs, antibody drug conjugates, polymers, fuel additives, organic synthesis and methodology development, fast-flow synthesis, formulations, polymorphs, and prodrugs. During his career, Drew has had the opportunity to prosecute multiple U.S. Food and Drug Administration Orange Book-listed patents.
Before joining the firm, Drew was a research chemist with a strong background in methodology development. Drew earned his doctorate at the University of Delaware, where he investigated the formation of carbon-carbon bonds using cheap and ubiquitous nickel catalysts to activate carbon-oxygen bonds, and the formation of previously unexplored carbon-carbon bonds using Lewis Acid catalysts to activate vinyl halides. Drew also worked as a postdoctoral fellow at Florida State University and the Department of Engineering at Virginia Commonwealth University on advances in novel copper catalysts for forming carbon-carbon bonds. During his postdoctoral research, Drew also developed an improved synthesis of potent anti-HIV drugs using a continuous reactor process (flow chemistry) to synthesize hydroxyl propyl adenine, a key component of many anti-HIV drugs.